InMed Pharmaceuticals (INM) investor relations material

Executive summary

• Announced a proposed merger with Mentari Therapeutics, aiming to create a combined company focused on migraine prevention therapies, expected to close by the end of 2026.

• Mentari secured an additional $200 million private placement, bringing total pre-closing financing to $490 million, extending the cash runway into 2029.

• Legacy pharmaceutical programs (INM-901, INM-089, INM-755) will be managed via Contingent Value Rights (CVRs) for current shareholders.

Financial highlights

• Reported net loss of $12.9 million for the fiscal year ended June 30, 2026, compared to $8.2 million in the prior year.

• Research and development expenses increased to $3.0 million from $2.8 million year-over-year.

• General and administrative expenses rose to $6.7 million from $5.4 million year-over-year.

• BayMedica, presented as discontinued operations, recorded sales of $3.2 million, down from $5.0 million year-over-year.

• Cash, cash equivalents, and short-term investments totaled $2.2 million as of June 30, 2026.

Outlook and guidance

• Merger with Mentari expected to close in Q4 2026, subject to regulatory and shareholder approvals.

• Combined company’s cash runway projected through 2029, supporting clinical milestones for migraine therapies.

• Ongoing efforts to monetize legacy pharmaceutical assets through strategic transactions.